Compare Oatly Group AB - ADR (OTLY) vs Revvity Inc (RVTY) Price & Performance

OTLY trades at $10.59, up 2.12% today, with a bearish technical signal but improving fundamentals. Revenue grew to $862.46M in 2025, and net losses narrowed to -$152.77M, reflecting margin improvements. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment. However, negative cash flows and high debt-to-asset ratio of 66.53% in 2025 pose risks. Analyst consensus is mixed with a $12.28 price target, indicating modest upside potential from current levels.

Outlook: OTLY shows operational progress with revenue growth and reduced losses, but profitability remains elusive. Investment opportunity hinges on sustained margin expansion and positive EBITDA. Key risks include cash burn, competitive pressures, and leverage. Investors should weigh turnaround potential against financial stability concerns.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.